Summary (tl;dr)

A new, highly mutated COVID-19 variant named BA.3.2, also dubbed "Cicada," is currently under global surveillance due to its significant number of mutations and potential for immune evasion, leading to increased public interest in new variants and their symptoms.

Essential Background

COVID-19, caused by the SARS-CoV-2 virus, continues to evolve, with new variants emerging periodically. The Omicron lineage and its descendants, such as JN.1 and XFG, have been the predominant strains in circulation in recent years. Public health efforts rely on genomic sequencing and wastewater surveillance to detect and track these viral changes, often identifying new variants in sewage data weeks before clinical samples.

The Full Story

Public health authorities, including the Centers for Disease Control and Prevention (CDC), are closely monitoring a new, heavily mutated COVID-19 variant known as BA.3.2, which has been nicknamed "Cicada." First identified in South Africa in November 2024, BA.3.2 has since spread to at least 23 countries and has been detected in wastewater samples across half of the United States. This variant is particularly noteworthy for its extensive number of mutations—approximately 70 to 75 in its spike protein—which is significantly higher than other recent strains like JN.1. This raises concerns about its ability to potentially reduce protection from existing vaccinations or previous infections. While clinical case numbers for BA.3.2 in the U.S. currently remain low, its widespread detection in wastewater suggests a potentially broader, unconfirmed circulation. In contrast, countries such as Denmark, Germany, and the Netherlands observed BA.3.2 accounting for around 30% of their sequenced cases between November 2025 and January 2026. Symptoms associated with BA.3.2, similar to other recent variants, are generally described as mild and cold-like, including a severe sore throat, congestion, and dry cough.

Why It Matters

The emergence of the BA.3.2 variant underscores the continuous evolution of SARS-CoV-2 and highlights the ongoing need for vigilance and public health surveillance. Its numerous mutations are a key concern, as they suggest a potential for immune evasion, meaning that current vaccines and prior infections might offer less protection against this particular strain. This situation prompts individuals to search for information on "new covid variant symptoms" and "covid symptoms 2026" as they seek to understand if the variant presents different signs of illness and how to protect themselves. Public health agencies are continuing genomic surveillance to track BA.3.2's spread and evaluate its overall impact on public health.

Geographic Location

• South Africa (first detection of BA.3.2 in November 2024)
• United States (BA.3.2 detected in half of states and 25 states via wastewater surveillance)
  • California, United States (BA.3.2 detected in wastewater)
  • San Francisco International Airport, California, United States (first US detection in a traveler from Netherlands)
  • New York, United States (BA.3.2 detected in wastewater)
  • Wyoming, United States (BA.3.2 detected in wastewater)
  • Missouri, United States (BA.3.2 detected in wastewater)
  • Hawaii, United States (BA.3.2 detected in wastewater)
• Denmark (BA.3.2 reached approximately 30% prevalence between November 2025 and January 2026)
• Germany (BA.3.2 reached approximately 30% prevalence between November 2025 and January 2026)
• Netherlands (BA.3.2 reached approximately 30% prevalence between November 2025 and January 2026)
• Mozambique (BA.3.2 spread in 2025)
• Western Australia, Australia (elevated BA.3.2 wastewater signals)